Compare iShares MSCI United Kingdom (FTSE) (EWU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs BIO-TECHNE Corp — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.48 (market cap $3.62B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 3.1× iShares MSCI United Kingdom (FTSE)'s market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and BIO-TECHNE Corp for 64 Days on average.
| EWU | TECH | |
|---|---|---|
Market Cap | $3.62B | $11.36B |
Volume | 923,896 | 5,390,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $72.61 |
52-Week Low | $41.34 | $43.31 |
Typical Hold Time | 46 Days | 64 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU is trading at $46.52, up 1.28% today, but faces significant technical headwinds with a bearish overall signal. The stock shows mixed technical indicators with oversold RSI levels but strong bearish momentum signals from ADX. Recent UK market volatility, driven by rising gilt yields and inflation concerns, creates a challenging environment for this UK-focused ETF.
The outlook remains cautious as UK economic pressures mount, with rising borrowing costs and energy price inflation creating headwinds. Investment opportunity exists for contrarian investors given oversold technical conditions, but risks include continued UK market volatility and persistent inflation pressures that could pressure UK equities.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
